ADVERSE EVENTS ASSOCIATED WITH ANTIBIOTIC THERAPY IN PEDIATRIC PRACTICE. THE ROLE OF PRE- AND PROBIOTICS IN THE PREVENTION OF ANTIBIOTIC-ASSOCIATED DIARRHEA

The era of antibiotics began in the mid-twentieth century, which resulted in changing the basic views on the treatment of infectious diseases and significantly increased the life expectancy among individuals on average by 20 to 30 years. The widespread uncontrolled use of antibacterial drugs has led to development of resistance to antibiotics and a number of adverse events, one of which is diarrhoea. Diarrhoea is caused by the use of antibiotics in 6–7% of cases. Pre- and probiotics are used to prevent diarrhoea. A study of the efficacy and safety of Ecomed (a powder to prepare a suspension containing 100 mg/5 ml azithromycin manufactured by AVVA RUS JSC (Russia) in combination with prebiotics lactulose) in comparison with azithromycin without lactulose was conducted in children with acute bacterial rhinosinusitis. A total of 100 patients were included in the study (50 boys and 50 girls) aged 3 to 14 years, who were divided into 2 groups: the main group consisted of 50 children (mean age 6.16 ± 2.78 years) who received Ecomed for 3 days; the control group of 50 children (mean age 6.9 ± 3.24 years) who received azithromycin for 3 days. The observation period was 2 months. During the observation period, the gastrointestinal tract state was evaluated for such symptoms as flatulence, bloating, frequency of bowel movements and consistency of feces. Feces were collected from children of both groups for gene sequencing by the 16s rRNA method during 4 visits: visit 1: before therapy, visit 2: 3 days after start of the therapy (end of the therapy), visit 3: 17 days after start of the therapy, visit 4: 60 days after start of the therapy. The study showed a significant difference between the microbiota profiles against the background of therapy with azithromycin and Ecomed. It was established that the total share of micro-organisms exposed to the drugs accounted for approximately 20–25%. The use of azithromycin provoked the development of intestinal dysbiosis according to the criteria for the deviation of the microbiota families, genera and species profile from the initial state, and according to the diagnostic signs of clinical symptomatology. An important observation was the fact that even after 2 months the dysbiotic state did not return to normal. The use of Ecomed containing a combination of azithromycin and lactulose reduced dysbiosis of the intestinal microbiota exposed to azithromycin. The main advantages were that opportunistic microorganisms had been prevented from growing against the background of azithromycin therapy and useful and other microorganisms had been preserved.

1. Маянский А.Н., Чеботарь И.В. Стафилокожковыебиопленки: структура, регуляция, отторжение. Журн микробиол, 2011, 1: 101-108.

2. Бехало В.А., Бондаренко В.М., Сысолятина Е.В., Нагурская Е.В. Иммунобиологические особенности бактериальных клеток медицинских биопленок. Журн Микробол, 2010, 4: 97-105.

3. Peeters E, Nelis HJ, Coenye T. Evaluation of the efficacy of disinfection procedures against Burkholderia cenocepacia biofilms. J Hosp Infect, 2008, 70: 361-368.

4. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev, 2002, 15: 167-193.

5. Turck D, Bernet J-P, Marx J, Kempf H, Giard P, Walbaum O, Bloch K. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. Journal of Pediatric Gastroenterology and Nutrition, 2003, 37(1): 22-26.

6. Bartlett J.G. Antibiotic-associated diarrhea. N Engl J Med, 2002, 346: 334-339.

7. Barakat Maha, El-Kady Zeinab, Mostafa Moha med, Naglaa Ibrahim and Hamdy Ghazaly. Anti bioticassociated Bloody Diarrhea in Infants: Clinical, Endoscopic and Histopatho logic Profiles. JPGN, 2011 Jan, 52(1).

8. McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibioticassociated diarrhea and Clostridium difficile infections. World Journal of Gastroenterology, 2016, 22(11): 3078-3104. doi: 10.3748/wjg.v22.i11.3078.

9. Esposito C, Roberti A, Turrà F, Cerulo M, Seve rino G, Settimi A, Escolino M.Frequency of AntibioticAssociated Diarrhea and Related Complications in Pediatric Patients Who Under went Hypospadias Repair: a Comparative Study Using Probiotics vs Placebo. Probiotics Antimic rob Proteins, 2017 Sep 4. doi: 10.1007/s12602-017-9324-4.

10. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive sffects of an antibiotic on human gut microbiota, as revealed by 16s rRNA sequencing. PLoS Biol, 2008, 6: 2383-2400.

11. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE.. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics, 2006 Aug, 118(2): 511-521.

12. Effects of the gut microbiota on obesity and glucose homeostasis, Thomas Greiner and Fredrik Ba¨ckhed Sahlgrenska Center for Cardiovascular and Metabolic Research/Wallenberg Laboratory, Department of Molecular and Clinical Medicine, University of Gothenburg, S-413 45 Gothenburg. Sweden Trends in Endocrinology and Metabolism, 2011 April, 22(4).

13. Mbakwa CA, Scheres L, Penders J, Mommers M, Thijs C, Arts ICW. Early Life Antibiotic Exposure and Weight Development in Children. The Journal of Pediatrics, 2016. doi: 10.1016/j.jpeds.2016.06.015.

14. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. The American Journal of Gastroenterology, 2013, 108(4): 478-498. Quiz 499. doi: 10.1038/ajg.2013.4.

15. Schutze GE, Willoughby RE, Committee on Infectious Diseases, & American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics, 2013, 131(1): 196-200.

16. Floch MH, Walker WA, Sanders ME, Nieuwdorp M, Kim AS, Brenner DA, Brandt LJ. Recommendations for Probiotic Use–2015 Update: Proceedings and Consensus Opinion. Journal of Clinical Gastroenterology, 2015, 49(Suppl 1): 69-73.

17. Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S , Johnston BC. Probiotics for the prevention of pe-diatric antibiotic-associated diarrhea a. Cochrane Database of Systematic Reviews, 2015, 12: CD004827. doi: 10.1002/14651858.CD004827.pub4.

18. Hafez MM. Interference between Lactobacilli and Group A Streptococcus Pyogenes: An Expansion to the Concept of Probiotics. ew Egyptian Journal of Microbiology, 2007, 17(1): 262–84.

19. Kõll P. Characterization of Oral Lactobacilli as Potential Probiotics for Oral Health. Oral microbiology and immunology, 2008, 23(2): 139–47

20. Simark-Mattsson C, Jonsson R, Emilson C-G, and Roos K. Final pH Affects the Interference Capacity of Naturally Occurring Oral Lactobacillus Strains against Mutans Streptococci. Archives of oral biology, 2009, 54(6): 602–7.

21. Van den Bogert B et al. Comparative Genomics Analysis of Streptococcus Isolates from the Human Small Intestine Reveals Their Adaptation to a Highly Dynamic Ecosystem. PloS one, 2013, 8(12): e83418.

22. Zoetendal EG, Raes J, van den Bogert B, Arumugam M, Booijink CCGM et al. The Human Small Intestinal Microbiota Is Driven by Rapid Uptake and Conversion of Simple Carbohydrates. The ISME journal, 2012, 6(7): 1415–26.